Delivery Order SPE2DB20D3303-SPE2DB25FA4FE
- Not listed
- The Defense Logistics Agency (DLA) awarded a $24,916.23 delivery order to AmerisourceBergen Drug Corp for NURTEC ODT 75 MG tablets (8-count units) on September 15, 2025, with an ultimate completion date of September 16, 2025. This firm fixed price delivery order represents a competitively awarded contract with no set-aside designation. The contract is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters as...
- The Defense Logistics Agency (DLA) awarded a $17,326.95 delivery order contract to AmerisourceBergen Drug Corp for NURTEC ODT 75 mg tablets (8-count packages) on August 27, 2025, with completion scheduled for August 28, 2025. This is a firm fixed-price, non-set-aside contract issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), which carries a $999.999 billion ceiling value through December 2026. AmerisourceBergen, headquartered in...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,304.62 to AmerisourceBergen Drug Corp for NURTEC ODT 75 mg tablets (8-count units) on July 28, 2025, with an ultimate completion date of July 29, 2025. This firm fixed-price delivery order represents a non-competitive award issued under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $1 billion global pharmaceutical support vehicle running through December 2026. The place...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $5,373.47 to AmerisourceBergen Drug Corp for NURTEC ODT 75 mg tablets (8-count packages) on September 9, 2025, with a completion date of September 10, 2025. This is a firm fixed-price delivery order with no set-aside designation, awarded through open competition. The order will be fulfilled from AmerisourceBergen's location in Conshohocken, Pennsylvania, which serves as the company's corporate headquarters and primary...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $17,463.12 to AmerisourceBergen Drug Corp for NURTEC ODT 75 mg tablets (8-count packaging) with a firm fixed price and no set-aside designation. The award was executed on September 10, 2025, with an ultimate completion date of September 11, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this delivery from its corporate office location in the...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $48,497.72 to AmerisourceBergen Drug Corp for NURTEC ODT 75 mg tablets (8-count packages) on August 22, 2025, with an ultimate completion date of August 25, 2025. This firm fixed-price, competitively awarded contract contains no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child order under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order valued at $17,461.79 to AmerisourceBergen Drug Corp for the supply of NURTEC ODT 75 mg tablets (8-count packages) under a firm fixed price contract type. This non-competitive delivery order was issued on June 16, 2025, with an ultimate completion date of June 17, 2025. The product will be delivered to the contractor's location in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order is...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $41,696.62 to AmerisourceBergen Drug Corp for NURTEC ODT 75 MG tablets (8-count units) on August 12, 2025, with an ultimate completion date of August 13, 2025. This is a firm fixed price, competitively awarded contract with no set-aside designation. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's...
- The Defense Logistics Agency awarded a $20,181.71 delivery order to AmerisourceBergen Drug Corp for NURTEC ODT 75 mg tablets (8-count units) on September 18, 2025, with an ultimate completion date of September 19, 2025. This competitively awarded, firm fixed-price contract with no set-aside designation represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) vehicle with DLA Troop Support Medical. The pharmaceutical product will be performed and shipped from...
- The Defense Logistics Agency awarded a delivery order valued at $16,979.99 to AmerisourceBergen Drug Corp for NURTEC ODT 75 mg tablets (8-count units) on August 27, 2025, with completion targeted for August 28, 2025. This firm fixed-price delivery order represents a non-competitive award under the contractor's existing contract vehicle with DLA. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical vendor for federal...
- SPE2DB20D3303Indefinite Delivery Contract
- SPE2DB20D3303-SPE2DB25FA4FEDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $17,812.02 to AmerisourceBergen Drug Corp for NURTEC ODT 75 mg tablets (8-count units) on September 25, 2025. This firm fixed-price delivery order is non-competitive and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $999.99 billion prime vendor agreement designated SPE2DX and running through December 2026. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with completion expected by September 26, 2025. NURTEC ODT is a migraine treatment medication used to treat acute migraine headaches. As a major pharmaceutical distributor and critical federal healthcare vendor, AmerisourceBergen supplies a comprehensive portfolio of medications and medical supplies to support military and veteran healthcare systems through the DLA Medical Supply Chain. This delivery order reflects the company's ongoing role in providing pharmaceutical products across multiple therapeutic domains to defense healthcare customers, including the Defense Health Agency and U.S. Coast Guard, through its competitively awarded global pharmaceutical support vehicle.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $17.8k | 9/25/25 |